Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective Study Investigating the Efficacy and Safety of a Scalp Cooling Device for the Prevention of Alopecia in Women Undergoing (Neo)Adjuvant Chemotherapy for Breast Cancer.
Carbognin L, Accetta C, Di Giorgio D, Fuso P, Muratore M, Tiberi G, Pavese F, D'Angelo T, Fabi A, Giannarelli D, Di Leone A, Magno S, Garganese G, Sanchez AM, Terribile DA, Franceschini G, Masetti R, Scambia G, Paris I. Carbognin L, et al. Among authors: fuso p. Curr Oncol. 2022 Sep 30;29(10):7218-7228. doi: 10.3390/curroncol29100569. Curr Oncol. 2022. PMID: 36290846 Free PMC article.
BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making.
Pavese F, Capoluongo ED, Muratore M, Minucci A, Santonocito C, Fuso P, Concolino P, Di Stasio E, Carbognin L, Tiberi G, Garganese G, Corrado G, Di Leone A, Generali D, Fragomeni SM, D'Angelo T, Franceschini G, Masetti R, Fabi A, Mulè A, Santoro A, Belli P, Tortora G, Scambia G, Paris I. Pavese F, et al. Among authors: fuso p. Cancers (Basel). 2022 Sep 21;14(19):4571. doi: 10.3390/cancers14194571. Cancers (Basel). 2022. PMID: 36230495 Free PMC article.
Let-7a-5p, miR-100-5p, miR-101-3p, and miR-199a-3p Hyperexpression as Potential Predictive Biomarkers in Early Breast Cancer Patients.
Fuso P, Di Salvatore M, Santonocito C, Guarino D, Autilio C, Mulè A, Arciuolo D, Rinninella A, Mignone F, Ramundo M, Di Stefano B, Orlandi A, Capoluongo E, Nicolotti N, Franceschini G, Sanchez AM, Tortora G, Scambia G, Barone C, Cassano A. Fuso P, et al. J Pers Med. 2021 Aug 20;11(8):816. doi: 10.3390/jpm11080816. J Pers Med. 2021. PMID: 34442460 Free PMC article.
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting.
Gamucci T, Pizzuti L, Sperduti I, Mentuccia L, Vaccaro A, Moscetti L, Marchetti P, Carbognin L, Michelotti A, Iezzi L, Cassano A, Grassadonia A, Astone A, Botticelli A, Magnolfi E, Di Lauro L, Sergi D, Fuso P, Tinari N, Barba M, Maugeri-Saccà M, Landucci E, Conti F, Sanguineti G, De Tursi M, Iafrate G, Giordano A, Ciliberto G, Natoli C, Vici P. Gamucci T, et al. Among authors: fuso p. J Cell Physiol. 2018 Mar;233(3):2313-2323. doi: 10.1002/jcp.26103. Epub 2017 Sep 27. J Cell Physiol. 2018. PMID: 28710865
Association of IL-8 and eNOS polymorphisms with clinical outcomes in bevacizumab-treated breast cancer patients: an exploratory analysis.
Di Salvatore M, Lo Giudice L, Rossi E, Santonocito C, Nazzicone G, Rodriquenz MG, Cappuccio S, Inno A, Fuso P, Orlandi A, Strippoli A, Capoluongo E, Astone A, Cassano A, Barone C. Di Salvatore M, et al. Among authors: fuso p. Clin Transl Oncol. 2016 Jan;18(1):40-6. doi: 10.1007/s12094-015-1334-7. Epub 2015 Jul 4. Clin Transl Oncol. 2016. PMID: 26141413
TRF2 as novel marker of tumor response to taxane-based therapy: from mechanistic insight to clinical implication.
Iachettini S, Terrenato I, Porru M, Di Vito S, Rizzo A, D'Angelo C, Petti E, Dinami R, Maresca C, Di Benedetto A, Palange A, Mulè A, Santoro A, Palazzo A, Fuso P, Stoppacciaro A, Vici P, Filomeno L, Di Lisa FS, Arcuri T, Krasniqi E, Fabi A, Biroccio A, Zizza P. Iachettini S, et al. Among authors: fuso p. J Exp Clin Cancer Res. 2024 Mar 9;43(1):75. doi: 10.1186/s13046-024-02998-w. J Exp Clin Cancer Res. 2024. PMID: 38459559 Free PMC article.
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
Fabi A, Carbognin L, Botticelli A, Paris I, Fuso P, Savastano MC, La Verde N, Strina C, Pedersini R, Guarino S, Curigliano G, Criscitiello C, Raffaele M, Beano A, Franco A, Valerio MR, Verderame F, Fontana A, Haspinger ER, Caldara A, Di Leone A, Tortora G, Giannarelli D, Scambia G. Fabi A, et al. Among authors: fuso p. NPJ Breast Cancer. 2024 Feb 5;10(1):13. doi: 10.1038/s41523-024-00619-5. NPJ Breast Cancer. 2024. PMID: 38316819 Free PMC article. No abstract available.
23 results